Neurimmune is a biopharmaceutical company that specializes in translating human immune memory into transformative therapeutics. With a focus on central nervous system (CNS) and protein aggregation diseases, Neurimmune's pipeline consists of drug candidates for conditions like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), fronto-temporal dementia, dementia with Lewy bodies, cardiomyopathy, and type 2 diabetes. Neurimmune utilizes its state-of-the-art Reverse Translational Medicine™ (RTM) technology platform to translate genetic information obtained from white blood cells into therapeutic antibodies.

These antibodies possess unique pharmacological activities, high affinity, target selectivity, excellent pharmacodynamics, and low immunogenicity. In 2007, Neurimmune licensed its antibody Aducanumab, a recombinant human monoclonal antibody targeting Abeta aggregates, to Biogen for the treatment and prevention of Alzheimer's disease. Since then, the collaboration between Neurimmune and Biogen has expanded, with Biogen acquiring exclusive rights to Neurimmune's antibodies against alpha-synuclein, tau, TDP-43, and C9orf72.

Additionally, Neurimmune is developing antibodies for the treatment of ALS, ATTR cardiomyopathy, and other treatment modalities such as small molecule programs and gene therapy. Led by a dedicated team of scientists and clinical experts, Neurimmune is committed to delivering innovative therapies driven by scientific discoveries